TREATMENT OF ROP WITH INTRAVITREAL APPLICATION OF BEVACIZUMAB (AVASTIN) - OUR EXPERIENCE

V. Chernodrinska, A. Oscar, N. Veleva, I. Petkova
Clinic of Ophthalmology, University Hospital "Alexandrovska", Sofia, Bulgaria

Introduction: Retinopaty of prematurity is a serious, vision-threatening condition occurring in prematurely born children. Contemporary treatment options include lasercoagulation of the peripheral retina, and in the past years with intravitreal application of Bevacizumab (Avastin)

Aim: To present our experience in the treatment of ROP with intravitreal application of Bevacizumab (Avastin).

Material: We present 10 cases (5 male and 5 female) of prematurely born children diagnosed in our clinic with bilateral ROP stage 3 with neovascularization, zone I or zone II. The youngest child was born in 24th gestetional week while the oldest one was born in 34th week. The lowest bodyweight observed at birth was 650g while the highest was 1600g.

Methods: All of the children were diagnosed with the use of a RetCam digital camera. The treatment was conducted with the application of 0.625 mg in 0.025 ml of solution.

Results: All of the children had significant improvement and neither of them needed additional laser treatment.

Conclusion: Retinopathy of prematurity remains a serious challenge for the clinicians. Timely diagnosis and the proper treatment option can significantly improve the visual outcome of the children. There is still not enough clinical data about the long term effect of the i.v. treatment with Avastin but the preliminary results are encouraging.